A difficulty of systemic treatment of retinopathies with PACAP is that the peptide has a short half-life in the serum due to the rapid degradation by the dipeptidyl-peptidase IV enzyme and that it is not known how it passes the blood–retina barrier. This evidence concerns the gene ADCYAP1 and retinal disorder.